The study on pancreatic cancer that promised a turning point has been withdrawn

I study Spanish which promised a turning point in the treatment of pancreatic cancer after the research conducted on 45 laboratory mice has been deleted from American scientific magazine who published it at the end of December, Pnasper “a serious and undeclared conflict of interest“.

The research had had global resonance because it concerns one of the tumors that are more difficult to treat and why the treatment tested on mice had led to a lasting healing and devoid of side effects.

Donations and financing

In a few months they arrived donations for more than three and a half million euros to finance these studiesbut now the magazine she realized that the study coordinatorlo Spaniard Mariano Barbacidit was in conflict of interest as co-founder e co-owner Of Vega Oncotargetsl’private company which produces the molecules employed for these cure.

Even two co-authors of the studythe collaborators Vasiliki Liaki e Carmen Guerrathey would have a financial bond with thebusiness.

The obligation to declare conflicts

In general terms the authors of medical research they can have ties con pharmaceutical companies o private companies but they have to declare it in calce all’itemwhich was not done. Barbacid and his two collaborators had not done so.

“The direction he decided to collect the item because of” he writes Pnas next to the title of the study. Lo studio claimed that sui topi there had beencomplete elimination from the cells dell’pancreatic ductal adenocarcinomathe most form widespread e aggressive Of pancreatic tumor.